These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36493968)

  • 1. Stability of Abuse-deterrent properties of PEO-based Abuse-deterrent formulation.
    Kibria G; Bandaranayake B; Zheng J; Lee S; Cruz C
    Int J Pharm; 2023 Jan; 631():122430. PubMed ID: 36493968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyethylene Oxide (PEO) Molecular Weight Effects on Abuse-Deterrent Properties of Matrix Tablets.
    Meruva S; Donovan MD
    AAPS PharmSciTech; 2019 Dec; 21(1):28. PubMed ID: 31858320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Drug Release Testing to Evaluate the Retention of Abuse-Deterrent Properties of Polyethylene Oxide Matrix Tablets.
    Meruva S; Rezaei L; Thool P; Donovan MD
    AAPS PharmSciTech; 2020 Oct; 21(7):270. PubMed ID: 33025237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abuse-deterrent features of an extended-release morphine drug product developed using a novel injection-molding technology for oral drug delivery.
    Skak N; Elhauge T; Dayno JM; Lindhardt K
    J Opioid Manag; 2017; 13(6):465-472. PubMed ID: 29308592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syringeability of morphine ARER, a novel, abuse-deterrent, extended-release morphine formulation.
    Kinzler ER; Pantaleon C; Iverson MS; Aigner S
    Am J Drug Alcohol Abuse; 2019; 45(4):377-384. PubMed ID: 30990363
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessing impact of formulation and process variables on in-vitro performance of directly compressed abuse deterrent formulations.
    Rahman Z; Yang Y; Korang-Yeboah M; Siddiqui A; Xu X; Ashraf M; Khan MA
    Int J Pharm; 2016 Apr; 502(1-2):138-50. PubMed ID: 26911416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended release pellets prepared by hot melt extrusion technique for abuse deterrent potential: Category-1 in-vitro evaluation.
    Butreddy A; Sarabu S; Dumpa N; Bandari S; Repka MA
    Int J Pharm; 2020 Sep; 587():119624. PubMed ID: 32653597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users.
    Webster LR; Smith MD; Lawler J; Lindhardt K; Dayno JM
    Pain Med; 2017 Sep; 18(9):1695-1705. PubMed ID: 27651510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Abuse-Deterrent Characteristics of Tablets Prepared via Hot-Melt Extrusion.
    Xu X; Siddiqui A; Srinivasan C; Mohammad A; Rahman Z; Korang-Yeboah M; Feng X; Khan M; Ashraf M
    AAPS PharmSciTech; 2019 Jun; 20(6):230. PubMed ID: 31227939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical Barrier Type Abuse-Deterrent Formulations: Mechanistic Understanding of Sintering-Induced Microstructural Changes in Polyethylene Oxide Placebo Tablets.
    Boyce HJ; Dave VS; Scoggins M; Gurvich VJ; Smith DT; Byrn SR; Hoag SW
    AAPS PharmSciTech; 2020 Jan; 21(3):86. PubMed ID: 31997096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferential Oxycodone Loss of Physically Manipulated Abuse Deterrent Oxycodone HCl Extended Release Tablets Prepared for Nasal Insufflation Studies.
    Meng Z; Boyce HJ; Sun D; Kinjo M; Raofi S; Li T
    Pharm Res; 2021 Jul; 38(7):1263-1278. PubMed ID: 34128146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of excipients and curing process on the abuse deterrent properties of directly compressed tablets.
    Rahman Z; Zidan AS; Korang-Yeboah M; Yang Y; Siddiqui A; Shakleya D; Khan MA; Cruz C; Ashraf M
    Int J Pharm; 2017 Jan; 517(1-2):303-311. PubMed ID: 27956191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing Abuse-Deterrent formulations utilizing Ion-Exchange resin complexation processed via Twin-Screw granulation for improved safety and effectiveness.
    Ram Munnangi S; Narala N; Lakkala P; Kumar Vemula S; Repka M
    Eur J Pharm Biopharm; 2024 Apr; 197():114230. PubMed ID: 38373555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
    Friedmann N; Marsman MR; de Kater AW; Burns LH; Webster LR
    J Opioid Manag; 2018; 14(6):437-443. PubMed ID: 30629280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An in vitro approach for evaluating the oral abuse deterrence of solid oral extended-release opioids with properties intended to deter abuse via chewing.
    Externbrink A; Sharan S; Sun D; Jiang W; Keire D; Xu X
    Int J Pharm; 2019 Apr; 561():305-313. PubMed ID: 30862508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Assessment of Nasal Insufflation of Comminuted Drug Products Designed as Abuse Deterrent Using the Vertical Diffusion Cell.
    Boyce H; Smith D; Byrn S; Saluja B; Qu W; Gurvich VJ; Hoag SW
    AAPS PharmSciTech; 2018 May; 19(4):1744-1757. PubMed ID: 29582347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Manufacturing Process on the Retention of Abuse-Deterrent Properties of PEO-Matrix Tablets.
    Rezaei L; Meruva S; Donovan MD
    AAPS PharmSciTech; 2021 Dec; 23(1):38. PubMed ID: 34961912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk based in vitro performance assessment of extended release abuse deterrent formulations.
    Xu X; Gupta A; Al-Ghabeish M; Calderon SN; Khan MA
    Int J Pharm; 2016 Mar; 500(1-2):255-67. PubMed ID: 26784976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human abuse potential studies of abuse-deterrent opioids: lessons from oral and intranasal studies with morphine abuse-deterrent, extended-release, injection-molded tablets.
    Webster LR; Viscusi ER; Brown C; Dayno JM
    Curr Med Res Opin; 2018 May; 34(5):893-901. PubMed ID: 29368961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users.
    Raofi S; Kinjo M; Sun D; Li Z; Boyce H; Natarajan K; Frost M; Zhao L; Luke M; Lionberger R; Kelsh D; Kim MJ
    Clin Transl Sci; 2021 Sep; 14(5):1977-1987. PubMed ID: 33982418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.